Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
22
resultados
Última actualización
16/10/2026 [07:01:00]
Resumen de: WO2026210378A1
The present invention refers to a composition comprising at least one nanometrized anthelmintic compound for use in treating a helminthic condition or disease in a subject in need, wherein the helminthic condition or disease is resistant to a non-nanometrized anthelmintic or antiparasitic compound; and a method for treating a helminthic condition or disease in a subject in need by administering a composition comprising at least one nanometrized anthelmintic compound, wherein the helminthic condition or disease is resistant to non-nanometrized anthelmintic or antiparasitic compounds.
Resumen de: US20260306572A1
0000 The present invention relates to compositions and methods for producing a drinkable aqueous dispersion of hydrophobic dietary ingredients, particularly whole-milled cinnamon, to enhance its dispersibility, bioavailability, and palatability. The invention overcomes the limitations of conventional cinnamon formulations by incorporating a triglyceride oil as a milling aid and dispersibility enhancer, in conjunction with a surfactant system, to facilitate wet bead milling and achieve submicron or nanoscale particle sizes. The resulting dispersion retains the complete bioactive profile of whole cinnamon, including fiber, essential oils, and polyphenols, while significantly improving aqueous compatibility and sensory characteristics. The formulation ensures long-term suspension stability, prevents sedimentation, and enables efficient absorption of bioactive compounds, making it suitable for incorporation into functional foods, nutraceuticals, and pharmaceutical applications.
Resumen de: WO2026209838A1
The invention relates to particles comprising a pharmacologically active ingredient selected from peptides and proteins at a comparatively high weight content. The particles are characterized by a certain particle size distribution and a certain shape. In particular, a comparatively high (i) polydispersity index, (ii) span and/or (iii) standard deviation of the particle size indicates a comparatively broad particle size distribution. The invention further relates to pharmaceutical compositions that contain the particles according to the invention.
Resumen de: WO2026204817A1
Steps (A), (B), and (C) are carried out to produce a lipid derivative to which a polyalkylene oxide of formula (1) described in the specification is bonded. Step (A) is a step for obtaining a compound of formula (3) described in the specification by reacting a compound of formula (2) described in the specification and a solid or liquid alkylating agent in the presence of an alkali metal salt in an organic solvent at 10-40°C. Step (B) is a step for obtaining a compound of formula (4) by reacting the compound of formula (3) in an aqueous solution having a pH adjusted to not more than 3.0. Step (C) is a step for obtaining a lipid derivative of formula (1) by reacting the compound of formula (4) and at least one compound selected from the group consisting of fatty acids, fatty acid anhydrides, and fatty acid chlorides in an organic solvent.
Resumen de: US20260306406A1
0000 The present invention provides a steroid-cationic lipid compound having a structure represented by formula (I), and use thereof. The compound can be used in the preparation of lipid nanoparticles (LNPs) for delivering a therapeutic agent and/or a prophylactic agent. The LNPs prepared by using the steroid-cationic lipid compound of the present invention have good stability and transfection efficiency. The LNPs are used for delivering nucleic acid, such as mRNA, and can efficiently and stably deliver a bioactive substance to a target cell or organ. In addition, the LNPs have high stability, can be used for developing a freeze-dried preparation of mRNA, can also be used for aerosol inhalation administration of mRNA, and can cause a high specific antibody response in an experimental animal body, and the compound is safer.
Resumen de: WO2026212577A1
There is provided a compound comprising a structure represented by general formula (1): wherein A comprises a lipid or derivatives thereof, a sterol or derivatives thereof, or a hydrophobic vitamin or derivatives thereof; R3 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, a chemical moiety capable of serving as a label for user recognition, or a chemical moiety capable of targeting biological entities; and G comprises one or more of the repeating units or polymeric units selected from the group consisting of a repeating unit or polymeric unit of general formula (1A), a repeating unit or polymeric unit of general formula (1B), and a repeating unit or polymeric unit represented by general formula (1C): wherein 191 R1, R2, R80, and R81 are each independently optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; R82 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; m ≥ 0; n ≥ 1; x ≥ 0; y ≥ 1; and B comprises a carbohydrate or derivatives thereof.
Resumen de: WO2026211883A1
There has been a need for providing a pharmaceutical composition for treating cerebral infarction suitable for treating human cerebral infarction. The foregoing problem can be solved by the following pharmaceutical composition. Specifically, the present invention provides a pharmaceutical composition for treating human cerebral infarction, the pharmaceutical composition containing lipid nanoparticles in which mRNA coding for a NeuroD1 protein is encapsulated, wherein the concentration of the mRNA coding for a NeuroD1 protein in the pharmaceutical composition is 0.01 mg/mL or greater.
Resumen de: US20260306665A1
0000 The present invention provides lipid nanoparticles that comprise a therapeutic agent and have an astrocyte targeting peptide linked to their surface. Suppressor RNAs that restrict transgene expression to the central nervous system or to astrocytes, in particular, are also provided. Methods of using the lipid nanoparticles and suppressor RNAs in combination of therapeutic mRNAs to treat a central nervous system injury in a subject are also provided.
Resumen de: WO2026210912A1
The purpose of one embodiment is to provide a reduced coenzyme Q10 composition that does not readily undergo a transformation to another crystal form. The one embodiment is a composition that contains reduced coenzyme Q10, reduced coenzyme Q11, and reduced coenzyme Q9, the composition being characterized in that, on a chromatogram obtained for the composition by high-performance liquid chromatography under the subsequent conditions, the area ratio (RQ11/RQ9) of a peak that includes the reduced coenzyme Q11 (RQ11) that has a relative retention time (RRT) of 1.45–1.49 relative to the retention time (RT) for a peak top for the reduced coenzyme Q10 and a peak that includes the reduced coenzyme Q9 (RQ9) that has a relative retention time (RRT) of 0.69–0.73 is at least 1.0. Column: C18 column (length 150 mm, inside diameter 4.6 mm). Mobile phase composition: CH3OH:C6H14=9:1 (v:v). Mobile phase flow rate: 1 ml/min. Detection wavelength: 190 nm.
Resumen de: AU2026202200A1
Aspects of the present disclosure provide for improved compositions of bioreducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are vaccine compositions comprising mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid. ar a r a r
Resumen de: US20260306419A1
A lipid nanoparticle (LNP) composition for delivering a nucleic acid drug, and a preparation method therefor and a use thereof. The composition prepared by mixing a steroid-cationic lipid compound with a helper lipid and a polyethylene glycol modified phospholipid has better stability and transfection efficiency. The use of an LNP to deliver a nucleic acid, such as mRNA, can efficiently and stably deliver a nucleic acid drug to a target cell or organ, and meanwhile, the LNP can be used for aerosol inhalation administration of the mRNA and can also be used for developing a lyophilized preparation of the mRNA. A higher specific antibody response can be induced in an experimental animal, and the compound has better safety.
Resumen de: US20260306606A1
0000 The present invention relates to the field of prevention of herpes infections, in particularly to a pharmaceutical composition for oromucosal administration for vaccination against cytomegalovirus infections and the use of cytomegalovirus glycoprotein B. The pharmaceutical composition comprises, as an active ingredient, cytomegalovirus glycoprotein B, which is releasably contained in the pharmaceutical composition in a carrier for oromucosal administration of physiologically active agents, comprising at least one flexible active layer of polymeric nanofibers in which cytomegalovirus glycoprotein B is releasably contained, and at least one cover layer of polymeric nanofibers.
Resumen de: US20260306614A1
Disclosed herein are nucleic acid vaccine compositions including one or more polynucleotides encoding one or more antigenic polypeptide, formulated within a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a nucleic acid vaccine, comprising reconstituting a film comprising purified NMP lipids in the presence of an ionizable lipid to produce a LNMP comprising the ionizable lipid, and loading into the LNMPs with one or more polynucleotides encoding one or more antigenic polypeptides.
Resumen de: WO2026210911A1
The purpose of one aspect of the present invention is to provide reduced coenzyme Q10 composition in which transformation to another crystal form is unlikely to occur. One aspect of the present invention is a composition containing reduced coenzyme Q10, decaprenylphenol, and reduced coenzyme Q11, the composition characterized in that in a chromatogram of the composition obtained by high-performance liquid chromatography under the conditions of using a C18 column (having a length of 150 mm and an inner diameter of 4.6 mm) and setting the mobile phase composition to be CH3OH:C6H14 = 9:1 (v:v), the mobile phase flow rate to be 1 ml/min, and the detection wavelength to be 190 nm, the area ratio (decaprenylphenol/RQ11) of a peak that includes the decaprenylphenol having a relative retention time (RRT) of 1.34 to 1.41 relative to a retention time (RT) of a peak top of the reduced coenzyme Q10 to a peak that includes the reduced coenzyme Q11 (RQ11) having a relative retention time (RRT) of 1.45 to 1.49 relative to said retention time (RT) is 0.01 to 1.5.
Resumen de: WO2026210909A1
One of the embodiments of the present invention addresses the problem of providing a reduced coenzyme Q10 composition in which the transformation to another crystal form is less likely to occur. One of the embodiments of the present invention is a composition containing reduced coenzyme Q10, reduced demethoxy Q10, and reduced coenzyme Q9, the composition being characterized in that, in a chromatogram of the composition which is obtained by high performance liquid chromatography under the conditions mentioned below, the area ratio (RD/RQ9) of a peak containing the reduced demethoxy Q10 (RD) of which the relative retention time (RRT) relative to the retention time (RT) of a peak top of the reduced coenzyme Q10 is 0.88-0.94 to a peak containing the reduced coenzyme Q9 (RQ9) of which the above-mentioned relative retention time (RRT) is 0.69-0.73 is 0.3 or more. Conditions: a column: C18 column (length: 150 mm, inner diameter: 4.6 mm); mobile phase composition: CH3OH:C6H14 = 9:1 (v/v); mobile phase flow rate: 1 ml/min; detection wavelength: 190 nm.
Resumen de: WO2026210910A1
The purpose of one embodiment of the present invention is to provide a reduced coenzyme Q10 composition which is unlikely to undergo a transition to another crystal form. One embodiment of the present invention is a composition containing a reduced coenzyme Q10, decaprenyl phenol, and a reduced coenzyme Q9, said composition being characterized in that when a chromatogram of said composition is obtained by means of high-performance liquid chromatography performed under the conditions of a C18 column (length 150 mm, inner diameter 4.6 mm), a mobile phase composition which is CH3OH:C6H14=9:1 (v:v), a mobile phase flow rate of 1 ml/min., and a detection wavelength of 190 nm, the area ratio (decaprenyl phenol/RQ9) of a peak containing the decaprenyl phenol, which has a relative retention time (RRT) of 1.34-1.41 relative to the retention time (RT) of the peak top of the reduced coenzyme Q10, to a peak containing the reduced coenzyme Q9 (RQ9), which has a relative retention time (RRT) of 0.69-0.73 relative thereto, is 0.1-10.0.
Resumen de: WO2026209607A1
The present invention relates to a pharmaceutical combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a nanoparticle whose surface exposes a carboxyl group (−C(=O)−OH). This nanoparticle is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the vaccine effect of the substance transported by the carrier. The nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below -10 mV, and a size of about 4 nm to about 500 nm. The invention also relates to such a combination for use as a medicament in a subject in need thereof, in particular for use as a vaccine in the treatment of a cancer, an infection, or an immune disease.
Resumen de: US20260306659A1
The present disclosure relates generally to compositions and methods for gene therapy, and more specifically to delivering mRNA-based therapeutics to immune cells in vivo.
Resumen de: US20260306865A1
A system is provided for use with a subject suffering from primary or metastatic solid tumors. The system includes nanoparticles including a magnetic metallic core and a phase-change material (PCM) surrounding the magnetic metallic core and configured to absorb latent heat of fusion by undergoing a phase change that occurs at a phase-change temperature of 42-80 degrees C. A radiofrequency (RF) transmitter is configured to transmit energy, in a pulse train alternating between high power and low power at a pulse frequency of 0.5 Hz-2 Hz, to at least a portion of the subject's body, such so that the nanoparticles are heated to the phase-change temperature of the PCM, store energy from the pulse train in the PCM as latent heat of fusion, and release the stored energy from the PCM during an entirety of each low power phase of the pulse train. Other embodiments are also described.
Resumen de: US20260306604A1
0000 Embodiments of the present disclosure pertain to a composition that includes a particle, an antigen, and a modulator. In some embodiments, the modulator includes, without limitation, an agonist, an activator of the immune system, or combinations thereof. In some embodiments, the antigen is operable to elicit an immune response in a subject against Mycobacterium tuberculosis. Additional embodiments of the present disclosure pertain to methods of treating or preventing tuberculosis in a subject by administering a composition of the present disclosure to the subject.
Resumen de: US20260306532A1
The present invention relates to a method for synthesising nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which a first composition/solution 1 containing an aluminium source and a source of an ion of an alkali metal M, in particular Na, is prepared anda second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular Na, is prepared. The solutions 1 and 2 being free of any organic structuring agent.The two compositions/solutions 1 and 2 are mixed, and the mixture is crystallised, Thenanoparticles thus formed are optionally separated.According to the invention, said first composition/solution 1 and the second composition/solution 2 both consist of the source and of an alkaline phosphate buffer (PBS).The present invention also relates to the nanoparticles obtained and compositions containing them.
Resumen de: WO2026209609A1
The present invention relates to a pharmaceutical combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a nanoparticle whose surface exposes a carboxyl group (−C(=O)−OH). This nanoparticle is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the vaccine effect of the substance transported by the carrier. The nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below -10 mV, and a size of about 4 nm to about 500 nm. The invention also relates to such a combination for use as a medicament in a subject in need thereof, in particular for use as a vaccine in the treatment of a cancer, an infection, or an immune disease.
Resumen de: WO2026213347A1
Provided herein are methods and systems for preparing a plurality of lipid nanoparticles (LNPs) and/or controlling the size and/or morphology of a plurality of a plurality of LNPs.
Resumen de: WO2026209612A1
The present invention relates to a combination of i) a carrier comprising at least one substance inducing or modulating an immune response in a subject in need thereof, and ii) a nanoprimer. The carrier is a lipoplex having a positive or a negative surface charge whose value, expressed as an absolute value, is between about 10 mV and about 70 mV, and a size between about 100 nm and about 600 nm. This carrier is capable of binding to receptors located on the surface of immune cells. The nanoprimer is a biocompatible nanoparticle designed to transiently occupy liver cells in order to potentiate the vaccine effect of the substance transported by the carrier. Concretely, the nanoprimer is a lipid-based, polymer-based, or protein-based nanoparticle, having a surface charge value below – 10 mV, and a size of about 4 nm to about 500 nm. This combination, designed to optimize the activation of antigen-specific effector immune cells and their differentiation into long-term memory cells, may be used as a medicament in a subject in need thereof, in particular as a prophylactic or therapeutic vaccine in the context of a cancer, an infection, or an immune disease.
Nº publicación: WO2026209106A1 08/10/2026
Solicitante:
INTER BIOSOLUTIONS APS [DK]
INTER BIOSOLUTIONS APS
Resumen de: WO2026209106A1
The invention relates to a method for producing a functional animal feed additive comprising the steps of: providing cashew nut shells with kernels; subjecting the cashew nuts to a deshelling process; thereby producing a first fraction comprising cashew nuts (kernel) with testa and a second fraction comprising cashew nut shells; and processing the second fraction to a third liquid fraction comprising anacardic acid, and a fourth fraction comprising nutshell residue by a separation process, where the temperature during the separation process is maintained below 90 °C such as in the range 40-80 °C.
BOPI
Sede Electrónica
